In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Gracell Biotechnologies (GRCL) Financial results for the second quarter of 2021.

17.08.2021

Non-GAAP net loss is -$0.04, that is $0.08 better than analysts' forecasts.

Cash and cash equivalents are $318.1 million as of June 30, 2021.